Mycobacterium tuberculosis mutations associated with reduced susceptibility to Linezolid

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2542-2544

  Zhang, Shuo ^a   Chen, Jiazhen ^b   Cui, Peng ^b   Shi, Wanliang ^a   Shi, Xiaohong ^c   Niu, Hongxia ^d   Chan, Denise ^e   Yew, Wing Wai ^e   Zhang, Wenhong ^b   Zhang, Ying ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d LANZHOU UNIVERSITY   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; LINEZOLID; RPLC PROTEIN; RRL PROTEIN; UNCLASSIFIED DRUG; RIBOSOMAL PROTEIN L3; RIBOSOME PROTEIN; RNA 23S; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; GENES, BACTERIAL; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84963772469     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02941-15     Document Type: Article

References (14)

1. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4-11. http://dx.doi.org/10.1093/jac/dks354.
2. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. 2003. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159-168. http://dx.doi.org/10.1086/345744.
3. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42:3251-3255.
4. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367:1508-1518. http://dx.doi.org/10.1056/NE JMoa1201964.
5. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. 2010. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 50:49-55. http://dx.doi.org/10.1086/648675.
6. Richter E, Rusch-Gerdes S, Hillemann D. 2007. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1534-1536. http://dx.doi.org/10.1128/AAC.01113-06.
7. Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. 2014. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistancein multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents 43:231-235. http://dx.doi.org/10.1016/j.ijantimicag.2013.12.007.
8. Hillemann D, Rusch-Gerdes S, Richter E. 2008. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 52:800-801. http://dx.doi.org/10.1128/AAC.011 89-07.
9. Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S. 2012. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 56:2743-2745. http://dx.doi.org/10.1128/AAC.06 227-11.
10. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53:5265-5274. http://dx.doi.org/10.1128/AAC.00871-09.
11. Zhang Y, Yew WW. 2015. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 19:1276-1289. http://dx.doi.org/10.5588/ijtld.15.0389.
12. Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC. 2008. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 52:2226-2227. http://dx.doi.org/10.1128/AAC.00414-07.
13. Zhang S, Chen J, Shi W, Liu W, Zhang WH, Zhang Y. 2013. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microb Infect 2:e34. http://dx.doi.org/10.1038/emi.2013.38.
14. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 56:4806-4815. http://dx.doi.org/10.1128/AAC.05546-11.